CoChat
Sign Up
Cited by 153

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

Dolton, Garry, Rius, Cristina, Wall, Aaron, Szomolay, Barbara, Bianchi, Valentina, Galloway, Sarah A.E., Hasan, Md Samiul, Morin, Théo, Caillaud, Marine E., Thomas, Hannah L., Theaker, Sarah, Tan, Li Rong, Fuller, Anna, Topley, Katie, Legut, Mateusz, Attaf, Meriem, Hopkins, Jade R., Behiry, Enas, Zabkiewicz, Joanna, Alvares, Caroline, Lloyd, Angharad, Rogers, Amber, Henley, Peter, Fegan, Christopher, Ottmann, Oliver, Man, Stephen, Crowther, Michael D., Donia, Marco, Svane, Inge Marie, Cole, David K., Brown, Paul E., Rizkallah, Pierre, Sewell, Andrew K.·2023·Cell
DOI 10.1016/j.cell.2023.06.020
Open this paper in CoChat — free account

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cell.2023.06.020

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 76

  1. Rossjohn, 2015, T cell antigen receptor recognition of antigen-presenting molecules, Annu. Rev. Immunol., 33, 169, 10.1146/annurev-immunol-032414-112334 · DOI
  2. Sharma, 2015, The future of immune checkpoint therapy, Science, 348, 56, 10.1126/science.aaa8172 · DOI · Paper page
  3. Rosenberg, 2015, Adoptive cell transfer as personalized immunotherapy for human cancer, Science, 348, 62, 10.1126/science.aaa4967 · DOI
  4. Xing, 2012, T cell tolerance: central and peripheral, Cold Spring Harb. Perspect. Biol., 4, 10.1101/cshperspect.a006957 · DOI
  5. Cole, 2007, Human TCR-binding affinity is governed by MHC class restriction, J. Immunol., 178, 5727, 10.4049/jimmunol.178.9.5727 · DOI
  6. Tan, 2015, T cell receptor binding affinity governs the functional profile of cancer-specific CD8+ T cells, Clin. Exp. Immunol., 180, 255, 10.1111/cei.12570 · DOI
  7. Andersen, 2016, Long-lasting complete responses in patients with metastatic melanoma after adoptive cell therapy with tumor-infiltrating lymphocytes and an attenuated IL2 Regimen, Clin. Cancer Res., 22, 3734, 10.1158/1078-0432.CCR-15-1879 · DOI
  8. Wooldridge, 2012, A single autoimmune T cell receptor recognizes more than a million different peptides, J. Biol. Chem., 287, 1168, 10.1074/jbc.M111.289488 · DOI
  9. Szomolay, 2016, Identification of human viral protein-derived ligands recognized by individual major histocompatibility complex class I (MHCI)-restricted T cell receptors, Immunol. Cell Biol., 94, 573, 10.1038/icb.2016.12 · DOI
  10. Whalley, 2020, GPU-accelerated discovery of pathogen-derived molecular mimics of a T cell insulin epitope, Front. Immunol., 11, 10.3389/fimmu.2020.00296 · DOI
  11. Ishikawa, 1995, Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth, Genomics, 26, 527, 10.1016/0888-7543(95)80171-H · DOI
  12. Nielsen, 1999, A family of insulin-like growth factor II mRNA-binding proteins represses translation in late development, Mol. Cell. Biol., 19, 1262, 10.1128/MCB.19.2.1262 · DOI · Paper page
  13. Morgan, 2006, Cancer regression in patients after transfer of genetically engineered lymphocytes, Science, 314, 126, 10.1126/science.1129003 · DOI · Paper page
  14. Borch, 2020, Future role for adoptive T cell therapy in checkpoint inhibitor-resistant metastatic melanoma, J. Immunother. Cancer, 8
  15. Gonzalez-Galarza, 2020, Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools, Nucleic Acids Res., 48, D783
  16. Galloway, 2019, Peptide super-agonist enhances T cell responses to melanoma, Front. Immunol., 10, 10.3389/fimmu.2019.00319 · DOI
  17. Berset, 2001, Expression of Melan-A/Mart 1 antigen as a prognostic factor in primary cutaneous melanoma, Int. J. Cancer, 95, 73, 10.1002/1097-0215(20010120)95:1<73::AID-IJC1013>3.0.CO;2-S · DOI
  18. Donia, 2017, Acquired immune resistance follows complete tumor regression without loss of target antigens or IFNgamma signaling, Cancer Res., 77, 4562, 10.1158/0008-5472.CAN-16-3172 · DOI
  19. Ekeruche-Makinde, 2013, Peptide length determines the outcome of TCR/peptide-MHCI engagement, Blood, 121, 1112, 10.1182/blood-2012-06-437202 · DOI
  20. Cole, 2017, Dual molecular mechanisms govern escape at immunodominant HLA A2-restricted HIV epitope, Front. Immunol., 8, 10.3389/fimmu.2017.01503 · DOI
  21. Purbhoo, 2007, The HLA A∗0201-restricted hTERT(540–548) peptide is not detected on tumor cells by a CTL clone or a high-affinity T cell receptor, Mol. Cancer Ther., 6, 2081, 10.1158/1535-7163.MCT-07-0092 · DOI
  22. Madura, 2015, Structural basis for ineffective T cell responses to MHC anchor residue-improved "heteroclitic" peptides, Eur. J. Immunol., 45, 584, 10.1002/eji.201445114 · DOI
  23. Marincola, 1994, Loss of HLA haplotype and B locus down-regulation in melanoma cell lines, J. Immunol., 153, 1225, 10.4049/jimmunol.153.3.1225 · DOI
  24. Cole, 2009, Germ line-governed recognition of a cancer epitope by an immunodominant human T cell receptor, J. Biol. Chem., 284, 27281, 10.1074/jbc.M109.022509 · DOI
  25. Madura, 2019, TCR-induced alteration of primary MHC peptide anchor residue, Eur. J. Immunol., 49, 1052, 10.1002/eji.201948085 · DOI
  26. Marincola, 1994, Locus-specific analysis of human leukocyte antigen class I expression in melanoma cell lines, J. Immunother. Emphasis Tumor Immunol., 16, 13, 10.1097/00002371-199407000-00002 · DOI
  27. Skowera, 2008, CTLs are targeted to kill beta cells in patients with type 1 diabetes through recognition of a glucose-regulated preproinsulin epitope, J. Clin. Invest., 118, 3390
  28. Johnson, 2009, Gene therapy with human and mouse T cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen, Blood, 114, 535, 10.1182/blood-2009-03-211714 · DOI
  29. Uhlén, 2015, Proteomics. Tissue-based map of the human proteome, Science, 347, 10.1126/science.1260419 · DOI · Paper page
  30. Pham, 2017, The expression of BTS-2 enhances cell growth and invasiveness in renal cell carcinoma, Anticancer Res., 37, 2853
  31. Fang, 2014, Overexpression of BST2 is associated with nodal metastasis and poorer prognosis in oral cavity cancer, Laryngoscope, 124, E354, 10.1002/lary.24700 · DOI
  32. Shi, 2020, Bone marrow stromal antigen 2 is a potential unfavorable prognostic factor for high-grade glioma, OncoTargets Ther., 13, 8723, 10.2147/OTT.S258631 · DOI
  33. Xu, 2020, BST2 promotes tumor growth via multiple pathways in hepatocellular carcinoma, Cancer Investig., 38, 329, 10.1080/07357907.2020.1769125 · DOI
  34. Cai, 2009, Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis, BMC Cancer, 9, 10.1186/1471-2407-9-102 · DOI
  35. Mahauad-Fernandez, 2014, Bone marrow stromal antigen 2 expressed in cancer cells promotes mammary tumor growth and metastasis, Breast Cancer Res., 16, 10.1186/s13058-014-0493-8 · DOI
  36. Dai, 2017, IGF2 mRNA binding protein-2 is a tumor promoter that drives cancer proliferation through its client mRNAs IGF2 and HMGA1, eLife, 6, 10.7554/eLife.27155 · DOI · Paper page
  37. Barghash, 2016, Elevated expression of the IGF2 mRNA binding protein 2 (IGF2BP2/IMP2) is linked to short survival and metastasis in esophageal adenocarcinoma, Oncotarget, 7, 49743, 10.18632/oncotarget.10439 · DOI
  38. Barghash, 2015, Overexpression of IGF2 mRNA-binding Protein 2 (IMP2/p62) as a feature of basal-like breast cancer correlates with short survival, Scand. J. Immunol., 82, 142, 10.1111/sji.12307 · DOI
  39. Dahlem, 2019, The insulin-like growth factor 2 mRNA binding protein IMP2/IGF2BP2 is overexpressed and correlates with poor survival in pancreatic cancer, Int. J. Mol. Sci., 20, 10.3390/ijms20133204 · DOI
  40. He, 2018, IGF2BP2 overexpression indicates poor survival in patients with acute myelocytic leukemia, Cell. Physiol. Biochem., 51, 1945, 10.1159/000495719 · DOI
  41. Kessler, 2015, IMP2/p62 induces genomic instability and an aggressive hepatocellular carcinoma phenotype, Cell Death Dis., 6, 10.1038/cddis.2015.241 · DOI
  42. Xu, 2019, Up-regulation of IGF2BP2 by multiple mechanisms in pancreatic cancer promotes cancer proliferation by activating the PI3K/Akt signaling pathway, J. Exp. Clin. Cancer Res., 38, 10.1186/s13046-019-1470-y · DOI · Paper page
  43. Donia, 2017, PD-1(+) polyfunctional T cells dominate the periphery after tumor-infiltrating lymphocyte therapy for cancer, Clin. Cancer Res., 23, 5779, 10.1158/1078-0432.CCR-16-1692 · DOI
  44. Cole, 2016, Hotspot autoimmune T cell receptor binding underlies pathogen and insulin peptide cross-reactivity, J. Clin. Invest., 126, 2191, 10.1172/JCI85679 · DOI
  45. Hundemer, 2006, Identification of a new HLA-A2-restricted T cell epitope within HM1.24 as immunotherapy target for multiple myeloma, Exp. Hematol., 34, 486, 10.1016/j.exphem.2006.01.008 · DOI
  46. Ebstein, 2016, Exposure to Melan-A/MART-126-35 tumor epitope specific CD8(+)T cells reveals immune escape by affecting the ubiquitin-proteasome system (UPS), Sci. Rep., 6, 10.1038/srep25208 · DOI
  47. Sewell, 2012, Why must T cells be cross-reactive?, Nat. Rev. Immunol., 12, 669, 10.1038/nri3279 · DOI
  48. Bulek, 2012, TCR/pMHC Optimized Protein crystallization Screen, J. Immunol. Methods, 382, 203, 10.1016/j.jim.2012.06.007 · DOI
  49. Müller, 2020, A T cell reporter platform for high-throughput and reliable investigation of TCR function and biology, Clin. Transl. Immunology, 9, 10.1002/cti2.1216 · DOI
  50. Theaker, 2016, T cell libraries allow simple parallel generation of multiple peptide-specific human T cell clones, J. Immunol. Methods, 430, 43, 10.1016/j.jim.2016.01.014 · DOI
  51. Laugel, 2007, Different T cell receptor affinity thresholds and CD8 coreceptor dependence govern cytotoxic T lymphocyte activation and tetramer binding properties, J. Biol. Chem., 282, 23799, 10.1074/jbc.M700976200 · DOI
  52. Rius, 2018, Peptide-MHC Class I tetramers can fail to detect relevant functional T cell clonotypes and underestimate antigen-reactive T cell populations, J. Immunol., 200, 2263, 10.4049/jimmunol.1700242 · DOI
  53. Dolton, 2018, Optimised peptide-MHC multimer protocols for detection and isolation of autoimmune T cells, Front. Immunol., 9, 10.3389/fimmu.2018.01378 · DOI
  54. Garboczi, 1992, A2-peptide complexes: refolding and crystallization of molecules expressed in Escherichia coli and complexed with single antigenic peptides, Proc. Natl. Acad. Sci. U.S.A., 89, 3429, 10.1073/pnas.89.8.3429 · DOI
  55. Andersen, 2018, T cells isolated from patients with checkpoint inhibitor resistant-melanoma are functional and can mediate tumor regression, Ann. Oncol., 29, 1575, 10.1093/annonc/mdy139 · DOI
  56. Hui-Yuen, 2011, Establishment of Epstein-Barr virus growth-transformed lymphoblastoid cell lines, J. Vis. Exp., 10.3791/3321 · DOI
  57. Hamilton, 2012, Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells, Br. J. Haematol., 158, 589, 10.1111/j.1365-2141.2012.09191.x · DOI
  58. Tungatt, 2015, Antibody stabilization of peptide-MHC multimers reveals functional T cells bearing extremely low-affinity TCRs, J. Immunol., 194, 463, 10.4049/jimmunol.1401785 · DOI
  59. Tan, 2017, Human leucocyte antigen class I-redirected anti-tumour CD4(+) T cells require a higher T cell receptor binding affinity for optimal activity than CD8(+) T cells, Clin. Exp. Immunol., 187, 124, 10.1111/cei.12828 · DOI
  60. Crowther, 2020, Genome-wide CRISPR-Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1, Nat. Immunol., 21, 178, 10.1038/s41590-019-0578-8 · DOI
  61. Wooldridge, 2010, CD8 controls T cell cross-reactivity, J. Immunol., 185, 4625, 10.4049/jimmunol.1001480 · DOI
  62. Bolotin, 2015, MiXCR: software for comprehensive adaptive immunity profiling, Nat. Methods, 12, 380, 10.1038/nmeth.3364 · DOI
  63. Shugay, 2018, VDJdb: a curated database of T cell receptor sequences with known antigen specificity, Nucleic Acids Res., 46, D419, 10.1093/nar/gkx760 · DOI
  64. Legut, 2018, CRISPR-mediated TCR replacement generates superior anticancer transgenic T cells, Blood, 131, 311, 10.1182/blood-2017-05-787598 · DOI
  65. Sanjana, 2014, Improved vectors and genome-wide libraries for CRISPR screening, Nat. Methods, 11, 783, 10.1038/nmeth.3047 · DOI · Paper page
  66. Boulter, 2003, Stable, soluble T cell receptor molecules for crystallization and therapeutics, Protein Eng, 16, 707, 10.1093/protein/gzg087 · DOI
  67. Laugel, 2005, Design of soluble recombinant T cell receptors for antigen targeting and T cell inhibition, J. Biol. Chem., 280, 1882, 10.1074/jbc.M409427200 · DOI
  68. Newman, 2005, Towards rationalization of crystallization screening for small- to medium-sized academic laboratories: the PACT/JCSG+ strategy, Acta Crystallogr. D Biol. Crystallogr., 61, 1426, 10.1107/S0907444905024984 · DOI
  69. McCoy, 2007, Phaser crystallographic software, J. Appl. Crystallogr., 40, 658, 10.1107/S0021889807021206 · DOI · Paper page
  70. Emsley, 2004, Coot: model-building tools for molecular graphics, Acta Crystallogr. D Biol. Crystallogr., 60, 2126, 10.1107/S0907444904019158 · DOI · Paper page
  71. Murshudov, 2011, REFMAC5 for the refinement of macromolecular crystal structures, Acta Crystallogr. D Biol. Crystallogr., 67, 355, 10.1107/S0907444911001314 · DOI
  72. Webb, 2014, Protein structure modeling with MODELLER, Methods Mol. Biol., 1137, 1, 10.1007/978-1-4939-0366-5_1 · DOI
  73. Shugay, 2015, VDJtools: unifying post-analysis of T cell receptor repertoires, PLoS Comput. Biol., 11, 10.1371/journal.pcbi.1004503 · DOI
  74. Graff-Dubois, 2002, Generation of CTL recognizing an HLA-A∗0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy, J. Immunol., 169, 575, 10.4049/jimmunol.169.1.575 · DOI
  75. Jäger, 2007, NY-BR-1 is a differentiation antigen of the mammary gland, Appl. Immunohistochem. Mol. Morphol., 15, 77, 10.1097/01.pai.0000213111.05108.a0 · DOI
  76. Tang, 2017, GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses, Nucleic Acids Res., 45, W98, 10.1093/nar/gkx247 · DOI · Paper page

Metadata

Authors
Dolton, G., Rius, C., Wall, A., Szomolay, B., Bianchi, V., Galloway, S. A. E., Hasan, M. S., Morin, T., Caillaud, M. E., Thomas, H. L., Theaker, S., Tan, L. R., Fuller, A., Topley, K., Legut, M., Attaf, M., Hopkins, J. R., Behiry, E., Zabkiewicz, J., Alvares, C., Lloyd, A., Rogers, A., Henley, P., Fegan, C., Ottmann, O., Man, S., Crowther, M. D., Donia, M., Svane, I. M., Cole, D. K., Brown, P. E., Rizkallah, P., & Sewell, A. K.
Venue
Cell
Publisher
Elsevier BV
Published
2023-08
Volume
186
Issue
16
Pages
3333-3349.e27
ISSN
0092-8674
DOI
10.1016/j.cell.2023.06.020
Cited by
153
References
1
Language
en
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review